Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 55 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-36.64%-52.50% - - 1.28M
+2.38%+3.43%+82.88%+115.89% 73.96B
-0.05%+21.17%+53.61%+93.99% 64.66B
-4.27%-0.99%-3.38%+475.61% 27.32B
-1.97%+20.38%-0.37%+0.48% 27.86B
+2.54%+12.76%+62.52%+27.89% 25.97B
-0.47%+5.08%+35.32%-14.63% 19.98B
-1.79%-4.84%+239.54%+414.48% 17.84B
+1.22%+2.98%+18.11%+530.59% 16.24B
-1.29%+6.09%+41.81%+154.45% 13.3B
Average -4.10%+6.18%+58.89%+199.86% 31.9B
Weighted average by Cap. +0.06%+8.21%+59.02%+160.74%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14